Achmea Investment Management B.V. Decreases Stock Position in Teva Pharmaceutical Industries Ltd. $TEVA

Achmea Investment Management B.V. cut its position in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 40.8% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 403,824 shares of the company’s stock after selling 277,863 shares during the quarter. Achmea Investment Management B.V.’s holdings in Teva Pharmaceutical Industries were worth $8,157,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Advisors Asset Management Inc. bought a new stake in Teva Pharmaceutical Industries in the 2nd quarter valued at about $41,000. Cromwell Holdings LLC raised its position in shares of Teva Pharmaceutical Industries by 40.3% in the third quarter. Cromwell Holdings LLC now owns 2,191 shares of the company’s stock valued at $44,000 after purchasing an additional 629 shares during the period. MAI Capital Management raised its position in shares of Teva Pharmaceutical Industries by 26.8% in the second quarter. MAI Capital Management now owns 3,293 shares of the company’s stock valued at $55,000 after purchasing an additional 697 shares during the period. Rothschild Investment LLC lifted its stake in shares of Teva Pharmaceutical Industries by 97.0% during the 3rd quarter. Rothschild Investment LLC now owns 2,738 shares of the company’s stock valued at $55,000 after buying an additional 1,348 shares in the last quarter. Finally, JFS Wealth Advisors LLC lifted its stake in shares of Teva Pharmaceutical Industries by 257.1% during the 3rd quarter. JFS Wealth Advisors LLC now owns 2,778 shares of the company’s stock valued at $56,000 after buying an additional 2,000 shares in the last quarter. Institutional investors own 54.05% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts recently weighed in on TEVA shares. Piper Sandler reiterated an “overweight” rating and issued a $41.00 price objective (up from $40.00) on shares of Teva Pharmaceutical Industries in a research note on Wednesday, March 4th. JPMorgan Chase & Co. increased their target price on Teva Pharmaceutical Industries from $28.00 to $35.00 and gave the stock an “overweight” rating in a research report on Tuesday, December 16th. Scotiabank raised their price target on Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the stock a “sector outperform” rating in a report on Thursday, January 29th. Jefferies Financial Group increased their price objective on Teva Pharmaceutical Industries from $29.00 to $40.00 and gave the stock a “buy” rating in a report on Tuesday, January 6th. Finally, Barclays raised their target price on Teva Pharmaceutical Industries from $35.00 to $38.00 and gave the stock an “overweight” rating in a research note on Friday, January 30th. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Teva Pharmaceutical Industries presently has a consensus rating of “Moderate Buy” and a consensus price target of $37.67.

Teva Pharmaceutical Industries Stock Down 1.6%

TEVA opened at $29.60 on Thursday. The business’s fifty day simple moving average is $32.78 and its 200 day simple moving average is $26.92. Teva Pharmaceutical Industries Ltd. has a 52 week low of $12.47 and a 52 week high of $37.35. The company has a quick ratio of 0.80, a current ratio of 1.04 and a debt-to-equity ratio of 1.89. The stock has a market cap of $34.04 billion, a PE ratio of 24.67, a P/E/G ratio of 10.07 and a beta of 0.72.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its quarterly earnings results on Wednesday, January 28th. The company reported $0.96 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.65 by $0.31. The firm had revenue of $4.71 billion during the quarter, compared to analyst estimates of $4.36 billion. Teva Pharmaceutical Industries had a return on equity of 46.28% and a net margin of 8.16%.The company’s revenue was up 11.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.71 earnings per share. Teva Pharmaceutical Industries has set its FY 2026 guidance at 2.570-2.770 EPS. As a group, research analysts expect that Teva Pharmaceutical Industries Ltd. will post 2.5 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Teva Pharmaceutical Industries news, EVP Richard Daniell sold 17,295 shares of the stock in a transaction that occurred on Thursday, March 5th. The shares were sold at an average price of $31.67, for a total transaction of $547,732.65. Following the transaction, the executive vice president directly owned 85,755 shares in the company, valued at $2,715,860.85. This trade represents a 16.78% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Christine Fox sold 7,924 shares of the company’s stock in a transaction on Thursday, March 5th. The shares were sold at an average price of $31.67, for a total transaction of $250,953.08. Following the completion of the sale, the executive vice president directly owned 84,905 shares of the company’s stock, valued at $2,688,941.35. This trade represents a 8.54% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 858,799 shares of company stock worth $28,185,035 over the last ninety days. Corporate insiders own 0.49% of the company’s stock.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.